¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"integration host factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet factor 3
    Ç÷¼ÒÆÇÀÎÀÚ3
  • platelet factor 4
    Ç÷¼ÒÆÇÀÎÀÚ4
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ħÀüÀÎÀÚ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • prolactin releasing factor
    ÇÁ·Î¶ôƾºÐºñÀÎÀÚ
  • properdin factor B
    ÇÁ·ÎÆä¸£µòBÀÎÀÚ
  • properdin factor D
    ÇÁ·ÎÆä¸£µòDÀÎÀÚ
  • properdin factor E
    ÇÁ·ÎÆä¸£µòEÀÎÀÚ
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • phantom scatter factor
    ÆÒÅè»ê¶õ°è¼ö
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • prolactin releasing factor
    ÇÁ·Î¶ôƾºÐºñÀ¯¹ßÀÎÀÚ
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ
  • psychogenic factor
    Á¤½Å¼º¿ä¼Ò
  • psychological factor
    ½É¸®¿ä¼Ò
  • psychosocial factor
    ½É¸®»çȸÀû¿äÀÎ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­), ÇöóÁÀÎÀÚ.
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­), ÇöóÁÀÎÀÚ(¡­ì×í­)
  • plasma thromboplastic factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ.
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ.
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet factor 4
    Ç÷¼ÒÆÇÀÎÀÚ(úìá³÷ùì×í­) 4
  • platelet factor 4=PF4
    Ç÷¼ÒÆÇÀÎÀÚ 4
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • platelet-activating factor (PAF)
    Ç÷¼ÒÆÇ Ȱ¼ºÈ­ÀÎÀÚ
  • platelet-activating factor (paf)
    Ç÷¼ÒÆÇȰ¼ºÈ­ÀÎÀÚ(úìá³÷ùüÀàõûùì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡ Áõ½ÄÀÎÀÚ
  • platelet-derived growth factor(PDGF)
    Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • power factor
    Ãâ·Â·ü(õóæ³ëÒ), ¿ª·ü(æ³ëÒ).
  • predisposing factor
    ¼ÒÀμº ¿äÀÎ, ¼±Çà¿äÀÎ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • dermonecrotic factor
    ÇǺα«»çÀÎÀÚ
  • diabetogenic factor
    ´ç´¢À¯¹ßÀÎÀÚ.
  • differentiation factor
    °¨º°¿äÀÎ, °¨º°¿ä¼Ò, °¨º°ÀÎÀÚ
  • dilution factor
    ¹±ÈûÀÎÀÚ(ÊÙËöËö), Èñ¼®ÀÎÀÚ.
  • dilution factor
    ¹±ÈûÀÎÀÚ(¡­ì×í­), Èñ¼®ÀÎÀÚ.
  • dose conversion factor
    ¼±·®º¯È¯°è¼ö
  • dose limiting factor
    ¼±·®ÇѵµÀÎÀÚ, ¼±·®Á¦ÇÑÀÎÀÚ
  • dose modifying factor
    ¼±·®¼ö½Ä°è¼ö
  • dose-reduction factor
    ¼±·®°¨¼Ò°è¼ö
  • drug resistance factor
    ¾àÁ¦³»¼ºÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • duplicate factor
    Áߺ¹ÀÎÀÚ.
  • early pregnancy factor(EPF)
    ÃʱâÀÓ½ÅÀÎÀÚ
  • edaphic factor
    ÅäÁöÀÎÀÚ(ÊÙËöËö).
  • elongation factor
    ¿¬ÀåÀÎÀÚ(¡­ì×í­).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • macrophage inhibition factor
    ´ë½Ä¼¼Æ÷ÀúÇØÀÎÀÚ(ÓÞãÝá¬øàîÁúªì×í­)
  • maize factor
    ¿Á¼ö¼ö ÀÎÀÚ(ì×í­)
  • maturation factor
    ¼º¼÷ÀÎÀÚ(à÷âÙì×í­)
  • migration enhancement factor
    À̵¿Ç×Áø ÀÎÀÚ(ì¹ÔÑùñòäì×í­)
  • migration inhibition factor
    À̵¿ÀúÇØ ÀÎÀÚ(ì¹ÔÑîÁúªì×í­)
  • mitogenic factor
    ºÐ¿­ÃËÁøÀÎÀÚ(ÝÂÖ®õµòäì×í­)
  • multiple factor hypothesis
    ´ÙÀÎÀÚ¼³(Òýì×í­àã)
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ(ãêÌèà÷íþì×í­)
  • oligomycin-sensitivity-conferring factor
    ¿Ã¸®°í¸¶À̽а¨¼ö¼ººÎ¿©ÀÎÀÚ(Êïáôàõݾæ¨ì×í­)
  • particle scattering factor
    ÀÔÀÚ »ê¶õÀÎÀÚ(Ø£í­ß¤Õ¯ì×í­)
  • pellagra-preventaive factor
    Æç¶ó±×¶ó ¿¹¹æÀÎÀÚ(çãÛÁì×í­)
  • permeability factor
    Åõ°ú ÀÎÀÚ(÷âΦì×í­)
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­)
  • plasma thromboplastic factor
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ(úìíìúìîûû¡à÷ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
TI inversion time; temporal integration; terminal ileum; thalassemia intermedia; therapeutic index; tho...
VLSI very large scale integration
VMI, VMIT visual-motor integration [test]
ANF alpha-naphthoflavone; American Nurses' Foundation; antineuritic factor; antinuclear factor; atrial n...
APF acidulated phosphofluoride; American Psychological Foundation; anabolism-promoting factor; animal pr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
Factor XII factor
EGF 125)I-epidermal growth factor
NGF 125)I-nerve growth factor
(125I)-EGF 125I)-labeled epidermal growth factor
125-I-EGF 125I-labelled epidermal growth factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • quality factor
    Á¤¼º ÀÎÀÚ, Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • release factor
    ¹æÃâ ÀÎÀÚ
  • releasing factor
    À¯¸® ÃËÁø ÀÎÀÚ, ¹æÃâ ÀÎÀÚ
  • resistance factor
    ³»¼º ÀÎÀÚ
  • Rh factor
    Rh ÀÎÀÚ
  • rheumsid factor
    ·ù¸¶Æ¼½º¾ç ÀÎÀÚ
  • risk factor
    À§Çè ¿äÀÎ, À§Çè ¿ä¼Ò, À§Çè ÀÎÀÚ
    °³ÀÎÀ̳ª ´Üü°¡ ÁúȯÀ̳ª Àå¾Ö¿¡ °É¸®±â ½±°Ô ÇÏ´Â ¿øÀÎÀÌ µÇ´Â ¿ä¼Ò·Î¼­ ¹Î°¨ÇÑ »ç¶÷µé¿¡¼­ ¹ß»ý ºóµµ¿Í Á¤µµ¸¦ Áõ°¡½ÃŲ´Ù.
  • safety factor
    ¾ÈÀü·ü
    ½Å°æ ¼¶À¯³ª ±Ù¼¶À¯ÀÇ ÈïºÐ Á¤µµ¿¡ À־ ÀÌ¹Ì ÈïºÐÇÑ °÷¿¡¼­, ¾ÆÁ÷ ÈïºÐÇϰí ÀÖÁö ¾ÊÀº ºÎºÐÀ¸·Î Àü·ù°¡ È帧À¸·Î½á ÈïºÐÀÌ ÀüµµÇϴµ¥, ÀÌ Àü·ù°¡ ½ÇÁ¦·Î ÈïºÐ½Ã۴µ¥ ÇÊ¿äÇÑ Àü·ù°ª.
  • self-associated rheumatoid factor complex

    self-care (ÀÚ°¡ Ä¡·á

  • sex factor
    ¼º ÀÎÀÚ
  • situational factor
    »óȲ ¿äÀÎ
  • socioeconomic factor
    »çȸ °æÁ¦Àû ¿äÀÎ
  • somatic factor
    ü¼º ¿äÀÎ
  • spreading factor
    È®»ê ÀÎÀÚ
  • stem cell factor
    °£ ¼¼Æ÷ ¿ä¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
rho factor <cell biology> Protein factors found in prokaryotes, especially E. Coli, involved in the termination of transcription. Mutations in rho may cause the RNA polymerase to read through from one operon to the next.
(23 Aug 1998)
mesodermal factor A protein that can induce the formation of kidney and muscle primordia in embryos.
(05 Mar 2000)
growth factor <biochemistry> A complex family of polypeptide hormones or biological factors that are produced by the body to control growth, division and maturation of blood cells by the bone marrow. They regulate the division and proliferation of cells and influence the growth rate of some cancers. These factors occur naturally but some can be synthesised using molecular biology techniques and are used clinically to stimulate normal white cell production following chemotherapy or bone marrow transplantation.
Examples include epidermal growth factor, platelet-derived growth factor, fibroblast growth factor. Insulin and somatomedin are also growth factors, the status of nerve growth factor is more uncertain. Perturbation of growth factor production or of the response to growth factor is important in neoplastic transformation.
(29 Sep 1997)
growth hormone-releasing factor <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone.
Synonym: somatoliberin, growth hormone-releasing factor.
(20 Sep 2002)
risk factor <statistics> A clearly defined occurrence or characteristic that has been associated with the increased rate of a subsequently occurring disease.
(14 Oct 1997)
Christmas factor <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
christmas factor assay A test used to measure the activity of a blood clotting factor IX (Christmas factor). This test may be used to evaluate excessive bleeding. Abnormally low factor IX assays may be seen in the following conditions: congenital deficiency of factor IX, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
ciliary neurotrophic factor <growth factor> Neurotrophic factor originally characterised as a survival factor for chick ciliary neurons in vitro.
Subsequently shown to promote the survival of a variety of other neuronal cell types and to promote the differentiation of bipotential O2A progenitor cells to type 2 astrocytes in vitro.
Molecular cloning and expression studies indicate that CNTF is a cytosolic protein. Developmental expression and regional distribution studies show that, unlike NGF, CNTF is not a target derived neurotrophic factor.
(18 Nov 1997)
migration-inhibitory factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
migration-inhibitory factor test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
citrovorum factor N5Formyl-5,6,7,8-tetrahydrofolic acid;the active form of folic acid which acts as a formyl group carrier in transformylation reactions; the calcium salt, leucovorin calcium, has therapeutic use.
Synonym: citrovorum factor, leucovorin.
(05 Mar 2000)
milk factor Member of the retrovirus subfamily Oncornavirinae, antigenically distinct from the murine leukaemia-sarcoma complex, that is associated with adenocarcinomatous tumours of the mammary gland, commonly latent in wild and laboratory mice and causing cancer only in genetically susceptible strains under certain hormonal influences.
Synonym: Bittner agent, Bittner virus, Bittner's milk factor, mammary cancer virus of mice, milk factor, mouse mammary tumour virus.
(05 Mar 2000)
clotting factor <haematology> A group of chemical constituents of the blood (factors I to XIII) which interact to make the blood clot.
(13 Nov 1997)
coagulation factor <haematology> Group of plasma protein substances (Factor I-XIII) contained in the plasma, which act in concert to bring about blood coagulation. Many of the factors contain EGF like domains.
(29 Sep 1997)
coagulation factor XI <haematology> A plasma serine protease with an apple domain.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á